Overview

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

Eligibility

Inclusion Criteria:

• Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
• Those who voluntarily signed a written personal information agreement to participate in this clinical study.
• Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.

Exclusion Criteria:

• Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
• Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
• Those who are expected to need insulin prescription during the study period
• Pregnant women, breast-feeding women